About: Complement activation during OKT3 treatment: a possible explanation for respiratory side effects

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Complement activation during OKT3 treatment: a possible explanation for respiratory side effects Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 1993

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 1993 (uk) article scientifique publié en 1993 (fr) im Mai 1993 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en mayu de 1993 (ast) scientific article published on 01 May 1993 (en)
publication date	wds:Q70758590-ADAF7F47-9B25-46C3-99ED-957DB53B7474
publication date	1993-05-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q70758590-652F4D6C-7497-442C-8EFE-034F7099574B
language of work or name	English
exact match	wds:Q70758590-746F5C81-7AB7-44CB-94CF-5CAA3DCC9FFF
exact match	https://scigraph.springernature.com/pub.10.1038/ki.1993.160
cites work	wds:Q70758590-004AADB4-095A-4A9C-8710-39836C910ED5 wds:Q70758590-07B991FA-EC66-4AC0-B065-674046160237 wds:Q70758590-08EDCEE3-84E1-4FF9-8F08-9B6C347183DA wds:Q70758590-0A49F8EE-A905-4EA0-AF3F-FCAFCDCAB10C wds:Q70758590-0D1A5B77-E171-42B3-A8D7-DD1A4CC69CBD wds:Q70758590-107D4615-0D5C-4973-BF87-1768B8C89DA7 wds:Q70758590-2172768D-F2AA-48F7-A11C-7B154931E1C8 wds:Q70758590-27A08CD7-86AF-4004-AD46-EA8E208D26D9 wds:Q70758590-2F06FB21-0224-4B83-9620-37FCACB3E770 wds:Q70758590-375BF8C1-A456-4C37-8B8C-95F05A942ECF wds:Q70758590-46130BB0-06DE-40B7-8BE0-4323A2136BED wds:Q70758590-485BC9D8-08A4-4A0C-8ADD-59F4186C8E5F wds:Q70758590-53136508-09DB-43C5-AF3C-8AF9D4931B6B wds:Q70758590-56512227-927C-493F-983E-F2F73B23ABC8 wds:Q70758590-6DA9B916-81B2-48E7-9F39-0E82C3BA4199 wds:Q70758590-73C2244B-3C9A-40C9-BC21-B21029A0699E wds:Q70758590-801A21BF-D95C-4F5C-A115-D55903117B9D wds:Q70758590-80CDE201-D87A-49A0-BB5A-96E060F7B756 wds:Q70758590-85F57EF7-8929-40EB-8C0E-A7220F93AD78 wds:Q70758590-9CDE8F3E-79D7-40A3-9225-6A8410173A85 wds:Q70758590-B1A5ED1F-887D-4FDE-A1A9-907DD7AC3704 wds:Q70758590-C6C39F3B-43BA-4AD1-BAEB-05F47415F832 wds:Q70758590-CAAB73F5-98AB-486F-99CE-050706D2F42C wds:Q70758590-CF359A1F-81DE-4F60-A057-425EFA82CDE8 wds:Q70758590-DC89879D-9382-4019-B258-380D8C1C61BA wds:Q70758590-DEEDF717-5A43-485C-BDBF-1DE94F7309AF wds:Q70758590-E010E2F3-6116-4B47-B041-564D4C99E0D2 wds:Q70758590-E6E60CBB-0982-44E0-A7A3-B0323C0CD542 wds:Q70758590-FC7DF59E-3CF3-49A2-A3A2-9B8188C64894
cites work	Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients Muromonab CD3. A review of its pharmacology and therapeutic potential Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation Release of inflammatory mediators from stimulated neutrophils. Tissue destruction by neutrophils OKT3 and pulmonary capillary permeability. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes A modified competitive inhibition radioimmunoassay for the detection of C3a. Use of 125I-C3 instead of 125I-C3a Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents Systemic complement activation, lung injury, and products of lipid peroxidation Transient adhesion of neutrophils to endothelium Neutrophil-endothelial cell interactions. Modulation of neutrophil adhesiveness induced by complement fragments C5a and C5a des arg and formyl-methionyl-leucyl-phenylalanine in vitro Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury Role of complement activation in a model of adult respiratory distress syndrome C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment OKT3 and cerebral oedema Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes Continuous cell activation is necessary for stable interaction of complement receptor type 3 with its counter-structure in the aggregation response of human neutrophils Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5). Advantages of rat monoclonal antibodies. Thromboembolic complications and dose of monoclonal OKT3 antibody Interference of complement with the binding of carcinoembryonic antigen to solid-phase monoclonal antibodies Interleukin-6 and neopterin in renal transplant recipients: a longitudinal study
author name string	wds:Q70758590-054126F1-390A-4AA6-A0D8-27B2CAE4FE53 wds:Q70758590-0C02CFD4-422F-4DAA-AC5D-1A844105FCEE wds:Q70758590-7550022E-8283-4420-8663-BEC8A98601CA wds:Q70758590-7DFD6F68-B347-4933-95BE-511E8591F511 wds:Q70758590-A38676AA-087A-4CA4-9623-9614055310A0 wds:Q70758590-A4A008C4-B356-48B1-8496-0575B2D107C0 wds:Q70758590-F4AA8FAC-C4EC-41BC-A45C-14E11897C971 wds:Q70758590-FF805924-BACB-4476-95D0-6591FF7EDB52
author name string	I J ten Berge E A van Royen C E Hack F J Bemelman P T Schellekens A van Dongen F N van Diepen M H Raasveld
rdfs:label	Complement activation during OKT3 treatment: a possible explanation for respiratory side effects (en) Complement activation during OKT3 treatment: a possible explanation for respiratory side effects (nl)
skos:prefLabel	Complement activation during OKT3 treatment: a possible explanation for respiratory side effects (en) Complement activation during OKT3 treatment: a possible explanation for respiratory side effects (nl)
name	Complement activation during OKT3 treatment: a possible explanation for respiratory side effects (en) Complement activation during OKT3 treatment: a possible explanation for respiratory side effects (nl)
title	wds:Q70758590-B41B6935-C7B2-4343-93A9-48F5AC060C54
title	Complement activation during OKT3 treatment: a possible explanation for respiratory side effects (en)
page(s)	wds:Q70758590-F3786377-AEBA-4001-905B-E8D63A9147F0
page(s)	1140-1149
instance of	wds:Q70758590-62EF5713-7FA4-4A4E-A8AA-A8EB395A0FA5
instance of	scholarly article
PubMed ID	wds:Q70758590-DE78392F-41FE-4124-964C-9E9722E29B03

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software